TCBP Announces Dosing of 5 New Patients in ACHIEVE

5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland, Sept. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK. Currently, ...